Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 675269, 7 pages
http://dx.doi.org/10.1155/2015/675269
Review Article

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy

Department of Pediatrics, Hematology/Oncology, University of Louisville, Louisville, KY 40202, USA

Received 31 July 2015; Accepted 31 August 2015

Academic Editor: Fabio Pastorino

Copyright © 2015 Michael A. Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ward, C. Desantis, A. Robbins, B. Kohler, and A. Jemal, “Childhood and adolescent cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 2, pp. 83–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. R. C. Ribeiro, E. Steliarova-Foucher, I. Magrath et al., “Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study,” The Lancet Oncology, vol. 9, no. 8, pp. 721–729, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Rehwald, H. Schulz, M. Reiser et al., “Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group,” Blood, vol. 101, no. 2, pp. 420–424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. K. Singavi, A. M. Harrington, and T. S. Fenske, “Post-transplant lymphoproliferative disorders,” Cancer Treatment and Research, vol. 165, pp. 305–327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1812–1821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Loke, J. N. Khan, J. S. Wilson, C. Craddock, and K. Wheatley, “Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia,” Annals of Hematology, vol. 94, no. 3, pp. 361–373, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. O'Hear, H. Inaba, S. Pounds et al., “Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia,” Cancer, vol. 119, no. 22, pp. 4036–4043, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Kantarjian, D. Thomas, J. Jorgensen et al., “Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study,” The Lancet Oncology, vol. 13, no. 4, pp. 403–411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Herrera, B. Bostrom, L. Gore et al., “A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia,” Journal of Pediatric Hematology/Oncology, vol. 31, no. 12, pp. 936–941, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Dancey, J. Violet, A. Malaroda et al., “A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma,” Clinical Cancer Research, vol. 15, no. 24, pp. 7701–7710, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Cooney-Qualter, M. Krailo, A. Angiolillo et al., “A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study,” Clinical Cancer Research, vol. 13, no. 18, pp. 5652s–5660s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Yankelevich, S. V. Kondadasula, A. Thakur, S. Buck, N.-K. V. Cheung, and L. G. Lum, “Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets,” Pediatric Blood and Cancer, vol. 59, no. 7, pp. 1198–1205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Shusterman, W. B. London, S. D. Gillies et al., “Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4969–4975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Roth, M. Linkowski, J. Tarim et al., “Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma,” Cancer, vol. 120, no. 4, pp. 548–554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Packer, R. Jakacki, M. Horn et al., “Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan,” Pediatric Blood and Cancer, vol. 52, no. 7, pp. 791–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-L. Couec, N. André, E. Thebaud et al., “Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends,” Pediatric Blood and Cancer, vol. 59, no. 1, pp. 34–38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Aguilera, C. Mazewski, J. Fangusaro et al., “Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience,” Child's Nervous System, vol. 29, no. 4, pp. 589–596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Venkatramani, M. Malogolowkin, T. B. Davidson, W. May, R. Sposto, and L. Mascarenhas, “A phase i study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors,” PLoS ONE, vol. 8, no. 7, Article ID e68416, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ebb, P. Meyers, H. Grier et al., “Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2545–2551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Bagatell, C. E. Herzog, T. M. Trippett et al., “Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors,” Clinical Cancer Research, vol. 17, no. 3, pp. 611–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. S. Pappo, S. R. Patel, J. Crowley et al., “R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4541–4547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Cacciavillano, C. Sampor, C. Venier et al., “A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies,” Pediatric Blood & Cancer, 2015. View at Publisher · View at Google Scholar
  25. M. Cartellieri, M. Bachmann, A. Feldmann et al., “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 956304, 13 pages, 2010. View at Publisher · View at Google Scholar
  26. A. Hombach, A. Wieczarkowiecz, T. Marquardt et al., “Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule,” The Journal of Immunology, vol. 167, no. 11, pp. 6123–6131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. R. J. Brentjens, M. L. Davila, I. Riviere et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Science Translational Medicine, vol. 5, no. 177, Article ID 177ra38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. C. R. Y. Cruz, K. P. Micklethwaite, B. Savoldo et al., “Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study,” Blood, vol. 122, no. 17, pp. 2965–2973, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” The New England Journal of Medicine, vol. 365, no. 8, pp. 725–733, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Grupp, M. Kalos, D. Barrett et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” The New England Journal of Medicine, vol. 368, no. 16, pp. 1509–1518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. S. L. Maude, N. Frey, P. A. Shaw et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” The New England Journal of Medicine, vol. 371, no. 16, pp. 1507–1517, 2014. View at Publisher · View at Google Scholar
  32. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial,” The Lancet, vol. 385, no. 9967, pp. 517–528, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. C. U. Louis, B. Savoldo, G. Dotti et al., “Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma,” Blood, vol. 118, no. 23, pp. 6050–6056, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. Maude, D. Barrett, D. T. Teachey, and S. A. Grupp, “Managing cytokine release syndrome associated with novel T cell-engaging therapies,” Cancer Journal, vol. 20, no. 2, pp. 119–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, “Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2,” Molecular Therapy, vol. 18, no. 4, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. Cheever, J. P. Allison, A. S. Ferris et al., “The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research,” Clinical Cancer Research, vol. 15, no. 17, pp. 5323–5337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Marin, E. Cribioli, B. Philip et al., “Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells,” Human Gene Therapy Methods, vol. 23, no. 6, pp. 376–386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. J. Orentas, D. W. Lee, and C. Mackall, “Immunotherapy targets in pediatric cancer,” Frontiers in Oncology, vol. 2, article 3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. M. Capitini, M. Otto, K. B. Desantes, and P. M. Sondel, “Immunotherapy in pediatric malignancies: current status and future perspectives,” Future Oncology, vol. 10, no. 9, pp. 1659–1678, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. K. B. Haworth, J. L. Leddon, C.-Y. Chen, E. M. Horwitz, C. L. Mackall, and T. P. Cripe, “Going back to class I: MHC and immunotherapies for childhood cancer,” Pediatric Blood and Cancer, vol. 62, no. 4, pp. 571–576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. T. S. Miest and R. Cattaneo, “New viruses for cancer therapy: meeting clinical needs,” Nature Reviews Microbiology, vol. 12, no. 1, pp. 23–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Cho, D. R. Shook, N. Shimasaki, Y.-H. Chang, H. Fujisaki, and D. Campana, “Cytotoxicity of activated natural killer cells against pediatric solid tumors,” Clinical Cancer Research, vol. 16, no. 15, pp. 3901–3909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. M. Rooney, C. A. Smith, C. Y. C. Ng et al., “Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients,” Blood, vol. 92, no. 5, pp. 1549–1555, 1998. View at Google Scholar · View at Scopus
  44. H. E. Heslop, C. Y. C. Ng, C. Li et al., “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nature Medicine, vol. 2, no. 5, pp. 551–555, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. Liu, B. Savoldo, H. Huls et al., “Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas,” Recent Results in Cancer Research, vol. 159, pp. 123–133, 2002. View at Google Scholar · View at Scopus
  46. A. Curti, L. Ruggeri, A. D'Addio et al., “Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients,” Blood, vol. 118, no. 12, pp. 3273–3279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Geller, S. Cooley, P. L. Judson et al., “A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer,” Cytotherapy, vol. 13, no. 1, pp. 98–107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. J. S. Miller, Y. Soignier, A. Panoskaltsis-Mortari et al., “Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer,” Blood, vol. 105, no. 8, pp. 3051–3057, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. E. G. Iliopoulou, P. Kountourakis, M. V. Karamouzis et al., “A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 12, pp. 1781–1789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Fujisaki, H. Kakuda, N. Shimasaki et al., “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,” Cancer Research, vol. 69, no. 9, pp. 4010–4017, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. T. K. Garg, S. M. Szmania, J. A. Khan et al., “Highly activated and expanded natural killer cells for multiple myeloma immunotherapy,” Haematologica, vol. 97, no. 9, pp. 1348–1356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Zhang, Y. Cui, N. Voong et al., “Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells,” Journal of Immunotherapy, vol. 34, no. 2, pp. 187–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. E. Rubnitz, H. Inaba, R. C. Ribeiro et al., “NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 955–959, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. K. A. McDowell, J. A. Hank, A. Jacquelyn et al., “NK cell-based immunotherapies in pediatric oncology,” Journal of Pediatric Hematology/Oncology, vol. 37, no. 2, pp. 79–93, 2015. View at Publisher · View at Google Scholar
  55. J. E. Rubnitz, H. Inaba, G. Kang et al., “Natural killer cell therapy in children with relapsed leukemia,” Pediatric Blood & Cancer, vol. 62, no. 8, pp. 1468–1472, 2015. View at Publisher · View at Google Scholar
  56. H. Inaba, D. Bhojwani, J. L. Pauley et al., “Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies,” British Journal of Haematology, vol. 156, no. 2, pp. 275–279, 2012. View at Publisher · View at Google Scholar
  57. D. H. J. Verhoeven, A. S. K. de Hooge, E. C. K. Mooiman et al., “NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways,” Molecular Immunology, vol. 45, no. 15, pp. 3917–3925, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Kabelitz and R. Medzhitov, “Innate immunity—cross-talk with adaptive immunity through pattern recognition receptors and cytokines,” Current Opinion in Immunology, vol. 19, no. 1, pp. 1–3, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Reis e Sousa, “Toll-like receptors and dendritic cells: for whom the bug tolls,” Seminars in Immunology, vol. 16, no. 1, pp. 27–34, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. C. L. Mackall, T. A. Fleisher, M. R. Brown et al., “Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy,” The New England Journal of Medicine, vol. 332, no. 3, pp. 143–149, 1995. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Bao, K. Dunham, and K. Lucas, “MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1299–1307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. D. K. Krishnadas, L. Bao, F. Bai, S. C. Chencheri, and K. Lucas, “Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1,” Tumor Biology, vol. 35, no. 6, pp. 5753–5762, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. D. K. Krishnadas, T. Shapiro, and K. Lucas, “Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma,” Pediatrics, vol. 131, no. 1, pp. e336–e341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. L. Lasky III, E. H. Panosyan, A. Plant et al., “Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas,” Anticancer Research, vol. 33, no. 5, pp. 2047–2056, 2013. View at Google Scholar · View at Scopus
  65. L. Bowman, M. Grossmann, D. Rill et al., “IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma,” Blood, vol. 92, no. 6, pp. 1941–1949, 1998. View at Google Scholar · View at Scopus
  66. R. F. Rousseau, A. E. Haight, C. Hirschmann-Jax et al., “Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma,” Blood, vol. 101, no. 5, pp. 1718–1726, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Hegde, A. J. Moll, T. T. Byrd, C. U. Louis, and N. Ahmed, “Cellular immunotherapy for pediatric solid tumors,” Cytotherapy, vol. 17, no. 1, pp. 3–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Thurner, I. Haendle, C. Röder et al., “Vaccination with mage-3a1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,” The Journal of Experimental Medicine, vol. 190, no. 11, pp. 1669–1678, 1999. View at Publisher · View at Google Scholar